Matching articles for "RiVive"
Addendum: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • October 2, 2023; (Issue 1686)
Since the publication of our articles entitled Drugs for
Opioid Use Disorder and In Brief: Over-the-Counter
Narcan Nasal Spray earlier this year, Narcan (Emergent),
a nasal spray that delivers 4 mg of the...
Since the publication of our articles entitled Drugs for
Opioid Use Disorder and In Brief: Over-the-Counter
Narcan Nasal Spray earlier this year, Narcan (Emergent),
a nasal spray that delivers 4 mg of the opioid antagonist
naloxone, has become available for sale over the counter
(OTC). According to the manufacturer, the retail price for
a box containing 2 doses is $44.99. Some insurance
companies have announced plans to cover OTC
purchase of the drug for their members.
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • September 4, 2023; (Issue 1684)
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.